磷酸盐-白蛋白比值对院外心脏骤停患者神经功能预后的预测价值:一项多中心观察性研究
该多中心观察性研究纳入2015年10月至2021年6月期间2397例成人院外心脏骤停(OHCA)复苏后存活患者,评估磷酸盐-白蛋白比值(PAR)对出院时不良神经功能结局(CPC评分3-5)和院内死亡的预测价值。结果显示,不良神经功能结局组与非不良组PAR分别为2.4 vs 1.4,院内死亡组与存活出院组PAR分别为2.5 vs 1.6;PAR预测不良神经功能结局的AUROC为0.81(95%CI 0.79-0.83),预测院内死亡的AUROC为0.76(95%CI 0.74-0.78)。多因素分析中,PAR与不良神经功能结局独立相关(OR 1.30,95%CI 1.15-1.37;p<0.001),与院内死亡也独立相关(OR 1.24,95%CI 1.12-1.38;p<0.001)。作者认为PAR是OHCA复苏后患者易于获取的独立预后指标,有助于预测结局。
要点
- 在2397例成人OHCA复苏后存活者中,不良神经功能结局组PAR为2.4,显著高于良好结局组的1.4。
- 院内死亡组PAR为2.5,显著高于存活出院组的1.6。
- PAR预测出院时不良神经功能结局(CPC 3-5)的AUROC为0.81(95%CI 0.79-0.83)。
- PAR预测院内死亡的AUROC为0.76(95%CI 0.74-0.78)。
- 多因素分析显示PAR与不良神经功能结局独立相关(OR 1.30,95%CI 1.15-1.37;p<0.001),与院内死亡独立相关(OR 1.24,95%CI 1.12-1.38;p<0.001)。
适用人群与场景
- 成人院外心脏骤停(OHCA)复苏后存活的患者,研究时间为2015年10月至2021年6月。
诊断标准与关键阈值
- 出院时神经功能结局采用大脑功能分类(CPC)评分评估,CPC 3-5定义为不良神经功能结局。
研究设计与关键结果
- 多中心观察性研究,纳入2397例成人OHCA复苏后存活患者;主要终点为出院时不良神经功能结局(CPC 3-5),同时评估院内死亡率。
- 不良神经功能结局组与非不良组PAR分别为2.4 vs 1.4;院内死亡组与存活出院组PAR分别为2.5 vs 1.6。
- PAR预测不良神经功能结局的AUROC为0.81(95%CI 0.79-0.83),预测院内死亡的AUROC为0.76(95%CI 0.74-0.78)。
- 多因素分析中,PAR与不良神经功能结局独立相关(OR 1.30,95%CI 1.15-1.37;p<0.001),与院内死亡独立相关(OR 1.24,95%CI 1.12-1.38;p<0.001)。
证据类型、等级与局限
- 证据类型:多中心观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为PAR是OHCA复苏后患者易于获取的独立预后指标,有助于医疗人员预测结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: In patients with out-of-hospital cardiac arrest (OHCA), early and accurate outcome prediction is crucial for making treatment decisions and informing their relatives. A previous study reported an association between high phosphate levels and unfavorable neurological outcomes after return of spontaneous circulation (ROSC); however, its prognostic value was insufficient when used independently. Therefore, this study aimed to validate the usefulness of the phosphate-to-albumin ratio (PAR) in predicting neurological outcomes and in-hospital mortality by incorporating albumin, another known prognostic indicator.
MATERIALS AND METHODS: This multicenter observational study included adult OHCA survivors from October 2015 to June 2021. The primary endpoint was an unfavorable neurological outcome at hospital discharge, defined as a cerebral performance category score of 3-5. The in-hospital mortality rates were also evaluated.
RESULTS: Of the 2397 adult OHCA survivors, PAR differed significantly between the unfavorable and favorable neurological outcome groups, as well as between the non-survival and survival to hospital discharge groups (2.4 vs 1.4, 2.5 vs 1.6, respectively). The area under the receiver operating characteristic curve (AUROC) value of the PAR for predicting unfavorable neurological outcome was 0.81 (95% confidence interval [CI], 0.79-0.83), and the AUROC value for predicting in-hospital mortality was 0.76 (95% CI, 0.74-0.78). In multivariable analysis, the PAR was independently associated with unfavorable neurological outcome (odds ratio [OR] 1.30, 95% CI 1.15-1.37; p < 0.001) and in-hospital mortality (OR 1.24, 95% CI 1.12-1.38; p < 0.001).
CONCLUSION: The PAR is a readily obtainable and independent prognostic indicator for patients with ROSC after OHCA, helping healthcare providers in predicting outcomes.
参考来源
- Yoo KH, Lee J, Oh J, et al. The prognostic value of the phosphate-to-albumin ratio in patients with OHCA: A multicenter observational study. Am J Emerg Med. 2023. PMID: 38183884. doi:10.1016/j.ajem.2023.12.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。